NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $19.00 price objective on the stock.

A number of other equities research analysts have also weighed in on NRXP. EF Hutton Acquisition Co. I raised shares of NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st. Ascendiant Capital Markets raised their price objective on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, September 12th.

NRx Pharmaceuticals Trading Up 4.0 %

NRXP opened at $1.31 on Monday. The company has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $2.15. The firm has a market cap of $15.84 million, a price-to-earnings ratio of -0.61 and a beta of 1.27. NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $7.33.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC acquired a new position in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned approximately 0.14% of NRx Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.